Supplementary Table 1 – JBI Critical Appraisal Checklists according to study design

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **JBI Critical Appraisal Checklist for Case Reports** | **Yes** | **No** | **Unclear** | **Not applicable** |
| Q1. Were the patient’s demographic characteristics clearly described? |  |  |  |  |
| Q2. Was the patient’s history clearly described and presented as a timeline? |  |  |  |  |
| Q3. Was the current clinical condition of the patient on presentation clearly described? |  |  |  |  |
| Q4. Were diagnostic tests or assessment methods and the results clearly described? |  |  |  |  |
| Q5. Was the intervention(s) or treatment procedure(s) clearly described? |  |  |  |  |
| Q6. Was the post-intervention clinical condition clearly described? |  |  |  |  |
| Q7. Were adverse events (harms) or unanticipated events identified and described? |  |  |  |  |
| Q8. Does the case report provide takeaway lessons? |  |  |  |  |
| **JBI Critical Appraisal Checklist for Case Series**  |  |  |  |  |
| Q1. Were there clear criteria for inclusion in the case series? |  |  |  |  |
| Q2. Was the condition measured in a standard, reliable way for all participants included in the case series? |  |  |  |  |
| Q3. Were valid methods used for identification of the condition for all participants included in the case series? |  |  |  |  |
| Q4. Did the case series have consecutive inclusion of participants? |  |  |  |  |
| Q5. Did the case series have complete inclusion of participants? |  |  |  |  |
| Q6. Was there clear reporting of the demographics of the participants in the study? |  |  |  |  |
| Q7. Was there clear reporting of clinical information of the participants? |  |  |  |  |
| Q8. Were the outcomes or follow up results of cases clearly reported? |  |  |  |  |
| Q9. Was there clear reporting of the presenting site(s)/clinic(s) demographic information? |  |  |  |  |
| Q10. Was statistical analysis appropriate? |  |  |  |  |
| **JBI Critical Appraisal Checklist for Cohort Studies** |  |  |  |  |
| Q1. Were the two groups similar and recruited from the same population? |  |  |  |  |
| Q2. Were the exposures measured similarly to assign people to both exposed and unexposed groups? |  |  |  |  |
| Q3. Was the exposure measured in a valid and reliable way? |  |  |  |  |
| Q4. Were confounding factors identified? |  |  |  |  |
| Q5. Were strategies to deal with confounding factors stated? |  |  |  |  |
| Q6. Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? |  |  |  |  |
| Q7. Were the outcomes measured in a valid and reliable way? |  |  |  |  |
| Q8. Was the follow up time reported and sufficient to be long enough for outcomes to occur? |  |  |  |  |
| Q9. Was follow up complete, and if not, were the reasons to loss to follow up described and explored? |  |  |  |  |
| Q10. Were strategies to address incomplete follow up utilized? |  |  |  |  |
| Q11. Was appropriate statistical analysis used? |  |  |  |  |